Skip to main content
. Author manuscript; available in PMC: 2022 Feb 26.
Published in final edited form as: N Engl J Med. 2021 Aug 11;385(9):803–814. doi: 10.1056/NEJMoa2034031

Figure 1. Participants and Administration of CIS43LS.

Figure 1

The VRC 612 trial was conducted in two parts. Because of restrictions related to coronavirus disease 2019, the controlled human malaria infection that was originally planned for Part A was canceled, and the trial was modified. Of the 18 participants enrolled in Part B, 15 underwent controlled infection in month 10 (October 2020): 9 of these participants had received CIS43LS and 6 were control participants.